DLK Investment Management LLC Buys 295 Shares of Danaher Co. (NYSE:DHR)

DLK Investment Management LLC increased its position in shares of Danaher Co. (NYSE:DHR) by 1.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 22,212 shares of the conglomerate’s stock after purchasing an additional 295 shares during the period. Danaher accounts for 2.4% of DLK Investment Management LLC’s investment portfolio, making the stock its 17th largest holding. DLK Investment Management LLC’s holdings in Danaher were worth $6,175,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tsfg LLC lifted its stake in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new stake in Danaher in the 1st quarter valued at $30,000. Finally, Richardson Financial Services Inc. acquired a new stake in Danaher during the 4th quarter valued at $42,000. 79.05% of the stock is owned by institutional investors.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of research reports. Stephens initiated coverage on shares of Danaher in a research note on Tuesday, October 1st. They set an “overweight” rating and a $315.00 target price for the company. The Goldman Sachs Group raised their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, Stifel Nicolaus raised their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Price Performance

Shares of DHR traded up $5.36 during mid-day trading on Friday, reaching $271.81. The company had a trading volume of 600,870 shares, compared to its average volume of 2,721,225. The company’s 50 day simple moving average is $270.44 and its 200 day simple moving average is $258.97. The company has a market capitalization of $196.30 billion, a price-to-earnings ratio of 47.33, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. During the same quarter last year, the business posted $2.05 earnings per share. The company’s quarterly revenue was down 2.9% on a year-over-year basis. Analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio is presently 19.18%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.